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The myosin light-chain 1/3 locus (MLC1/3) is regulated by two promoters and a downstream enhancer
element which produce two protein isoforms in fast skeletal muscle at distinct stages of mouse embryogenesis.
We have analyzed the expression of transcripts from the internalMLC3 promoter and determined that it is also
expressed in the atria of the heart. Expression from the MLC3 promoter in these striated muscle lineages is
differentially regulated during development. In transgenic mice, theMLC3 promoter is responsible for cardiac-
specific reporter gene expression while the downstream enhancer augments expression in skeletal muscle.
Examination of the methylation status of endogenous and transgenic promoter and enhancer elements indi-
cates that the internal promoter is not regulated in a manner similar to that of the MLC1 promoter or the
downstream enhancer. A GATA protein consensus sequence in the proximalMLC3 promoter but not theMLC1
promoter binds with high affinity to GATA-4, a cardiac muscle- and gut-specific transcription factor. Mutation
of either the MEF2 or GATA motifs in the MLC3 promoter attenuates its activity in both heart and skeletal
muscles, demonstrating that MLC3 expression in these two diverse muscle types is dependent on common
regulatory elements.
Although embryologically distinct, striated myocytes in the
skeletal and cardiac muscle lineages share many specialized
gene products. Investigations into the molecular mechanisms
involved in the expression of these skeletal and cardiac genes
have revealed that both distinct and common regulatory re-
gions are responsible for their expression. Distinct regulatory
regions of several genes have been shown in vivo to activate
transcription either in skeletal or cardiac muscle tissue (30, 39,
53). Conversely, skeletal and cardiac muscle-specific expres-
sion of other striated genes has been shown to be modulated in
vitro or in vivo by the same cis regions and elements (28, 49, 55,
63). Such results support the hypothesis that certain shared
regulatory elements are present in the two striated muscle
lineages.
Multiple regulatory factors involved in differentiation of
skeletal muscle lineage have been recently characterized (re-
viewed in reference 66). The myogenic determination factors,
MyoD, myogenin, myf-5, and mrf-4, have been shown to bind
to the regulatory regions of muscle-specific genes through E-
box consensus sequences and thereby activate their transcrip-
tion. Additionally, overexpression of this class of proteins in
nonmuscle cells will convert them to a skeletal muscle pheno-
type. Isolation of a similar class of proteins which will convert
cells to the cardiac lineage has not been as successful. How-
ever, several factors which are involved in the establishment of
the cardiac muscle cell lineage and cardiac-muscle specific
gene expression have recently been identified. An example of
the former is the homeobox gene Nkx-2.5, which is necessary
for correct cardiac muscle morphogenesis and ventricular gene
expression (43). Transcription factors expressed in cardiac
muscle cells include the GATA-4 protein, which contains a
zinc finger DNA binding domain (2), and members of the
MADS protein family, MEF2, isoforms of which are found in
skeletal and cardiac muscles (72). GATA-4 has been shown to
activate cardiac muscle-specific transcription of the rat B-type
natriuretic peptide (rBNP), cardiac troponin C, and a-myosin
heavy chain (a-MHC) regulatory regions (23, 29, 47). MEF2
isoforms are necessary for the transcriptional activation of
both cardiac and skeletal genes (21, 48, 51). Moreover, disrup-
tion of the singleMEF2 gene in Drosophila melanogaster blocks
the differentiation of all smooth and striated muscles (40).
These results further indicate that both separate and common
transcription factors are involved in the differentiation of skel-
etal and cardiac muscles.
To further delineate the regulatory mechanisms involved in
striated muscle gene expression, we have examined the expres-
sion of MLC3, the fast alkali light-chain isoform encoded by
the internal promoter of the MLC1/3 locus. This locus consists
of two widely separated promoters, MLC1 and MLC3, and a
distal downstream enhancer element which generates two tran-
scripts which vary in their two 59 exons and contain five com-
mon 39 exons (Fig. 1) (12, 54, 56). Transcription from the two
promoters occurs at developmentally distinct stages (4, 42).
The MLC1 promoter and enhancer elements are essential for
the expression of a reporter construct in skeletal muscle cell
lines, although the MLC3 promoter appears to contain inde-
pendent transcriptional activity (11, 57, 60). MLC1 promoter
and enhancer elements driving a chloramphenicol acetyltrans-
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ferase (CAT) reporter gene in transgenic mice display correct
temporal and spatial expression in fast fibers (58). Unexpect-
edly, a rostrocaudal gradient of expression is present in the
intercostal musculature (13). This expression pattern is estab-
lished early in development, is maintained in culture, and is
correlated with a gradient of methylation in the downstream
enhancer (14, 24, 25).
In this study we demonstrate that MLC3 is expressed in
cardiac tissue. This transcript is primarily in the atria and
precedes skeletal muscle expression during development. We
assay promoter and enhancer elements in vivo by generating
transgenic mice carrying a minimal MLC3 promoter region
driving a CAT reporter construct with or without the down-
stream enhancer element. We find that both temporal and
spatial transgene expression patterns in the cardiac muscles of
these mice are solely dependent on theMLC3 promoter, which
is also able to activate moderate levels of expression in most
adult skeletal muscles. The addition of a downstream enhancer
is necessary for high levels of expression in skeletal muscle and
for expression in a larger number of muscle groups. The ex-
amination of the methylation status of promoter and enhancer
elements of the endogenous and transgenic regulatory ele-
ments reveals differential mechanisms that regulate the regu-
latory regions of this locus: the MLC1 promoter and MLC
enhancer exhibit skeletal muscle-specific demethylation while
theMLC3 promoter is ubiquitously demethylated. In addition,
delineation of MLC3 promoter elements indicates that a dou-
ble GATA element present exclusively in the MLC3 promoter
binds in a sequence-specific manner to the GATA protein,
GATA-4. Furthermore, both the GATA and MEF2 cis ele-
ments in the MLC3 promoter are necessary but not individu-
ally sufficient to activate expression in cardiac and skeletal
muscle. These results demonstrate a new role for GATA ele-
ments in striated muscle.
MATERIALS AND METHODS
Vectors and site-directed mutagenesis. Plasmid MLC32HCAT was generated
by deletion of the internal HindIII site of rat MLC3CAT (12) and the insertion
of a HindIII linker into the downstream SmaI restriction site. Rat enhancer
fragments were cloned into the BamHI site to generate MLC32HCAT180 and
MLC32HCAT920. Plasmid p628Luc was prepared by subcloning of a 628-bp
HindIII MLC3 promoter fragment into pGL2-basic (Promega). The enhancer
fragment from pMLC1CAT920 (53) was subsequently cloned into the down-
stream BamHI site (p628Luc920). Promoter deletions were constructed by di-
gestion of the entire MLC3 promoter with ApaI (position 2434), AflII (position
2257), or AvrII (position 2147), filling in with DNA polymerase (Klenow frag-
ment) to generate a blunt end, and digestion with HindIII. The resulting pro-
moter subfragments were recloned into pGL2-basic.
The MEF2 site and the GATA consensus binding sites in the rat MLC3
promoter were mutated by PCR (31) with the following oligonucleotides: CTG
GAT TCC GAC CAC TCG CCC TAG G for the MEF2 mutant and GTG AAA
FIG. 1. MLC1/3 locus and regulatory regions used in transgenic animals. Organization of exons and regulatory regions in the rat MLC1/3 locus (12, 50). The
locations of the two promoters and the downstream enhancer are indicated. (Top) Transcripts and exons detected by riboprobe are indicated. (Middle) Arrangement
of regulatory regions used in MLC3CAT transgenic animals. Transgenic constructs contained a 628-bp MLC3 promoter region driving the transcription of a CAT
reporter gene. Some constructs also contained a downstream 920-bp or minimal 180-bp enhancer element (63). (Bottom) Sequence comparison of MLC3 promoter
regions in several vertebrates. Consensus sequences for potential striated muscle regulator elements are stippled (per reference 56). The MaeII restriction site assayed
for genomic methylation is also indicated.
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TCC GCC ACT CGC CAT GAG G for the GATA mutant. The MEF2 mutated
sequence (mutated bases are indicated by underlining) was previously shown not
to bind to the MEF2 protein (1). The GATA site was mutated at bases essential
for the high-affinity binding of GATA factors (2, 36, 46, 68).
In vitro transcription-translation and EMSAs. Coupled in vitro transcription-
translations were carried out with 1.5 mg of a circular GATA-4 expression
plasmid (gift of M. Parmacek) and T7 RNA polymerase in a rabbit reticulocyte
kit (Promega) according to the manufacturer’s instructions. For electrophoretic
mobility shift assays (EMSAs), 2 ml of a 50-ml rabbit reticulocyte reaction mix-
ture either with or without added plasmid was mixed with 5 ml of 43 buffer (40
mM HEPES [N-2-hydroxyethylpiperazine-N9-2-ethanesulfonic acid; pH 7.8], 200
mM potassium glutamate, 20.0 mM MgCl2, 4.0 mM EDTA, 20% glycerol) (15),
0.1 mg of sonicated salmon sperm DNA (Sigma), and cold competitor oligonu-
cleotides in a final volume of 19 ml. Reaction mixtures were incubated at room
temperature for 10 min, 1.0 ml (0.1 pmol) of the 32P-end-labelled probe was
added (described below), and the reaction mixtures were incubated on ice for 30
min. Samples were loaded on a 5% nondenaturing polyacrylamide gel and
separated by electrophoresis in 0.53 Tris-borate-EDTA (TBE) at 200 V.
The following complementary 27-mers with overhanging ends were synthe-
sized for EMSAs: wild-type GATA-F, TGTGAAATCCGATACTAGATATGA
GGT; wild-type GATA-R, ACTGACCTCATATCTAGTATCGGATTT; mu-
tant GATA-F, TGTGAAATCCGCCACTCGCCATGAGGT; and mutated
GATA-R ACTGACCTCATGGCGAGTGGCGGATTT. The GATA motif was
mutated to the same bases (indicated by underlining) as those described above
for the mutant MLC3 reporter construct. Annealed wild-type GATA oligonu-
cleotides (1.0 pmol) were end labelled with the Klenow fragment (Promega).
Unlabelled annealed oligonucleotides were used as cold competitors.
Transgenic mice. MLC3CAT expression cassettes contained in a 2.2-, 2.4-, or
3.1-kb HindIII fragment were excised from pMLC32HCAT, pMLC32HCAT180,
or pMLC32HCAT920, respectively (Fig. 1), and injected into the pronuclei of
fertilized mouse eggs as described previously (27). Potential founders were
screened for transgene integration by tail blotting with the 32P-labelled CAT
DNA probe (58). Founder lines were established by mating transgene-positive
animals to C57BL/6 mice. F1 progeny were checked for presence of the transgene
by PCR amplification of tail genomic DNA with primers specific for the CAT
gene. The copy number was determined by digestion of 10 mg of genomic DNA
with EcoRI followed by Southern blot analysis with the CAT probe. The signal
intensity for each transgenic line was compared with that of a control transgenic
line which contained 40 copies (MLCCAT, line 7) (58). All transgenic lines
contained less than 40 copies of their respective transgenes with the exception of
line 1 which contained more than 200 copies (data not shown). CAT activity was
assayed in adult heterozygotes (5 weeks or older).
Cardiac injections of plasmid DNA. Cardiac injections of plasmid DNA were
performed as previously described (34). Briefly, 5 mg of test plasmid and 0.2 mg
of Rous sarcoma virus CAT control plasmid were coinjected directly into the
apex of the left ventricles of anesthetized adult female Wistar rats. Rats were
sacrificed 5 days after injection. The apical two-thirds of the heart was homog-
enized in homogenization buffer (1.5 ml/mg of tissue). A CAT assay was per-
formed chromatographically with 15 ml of the homogenate (3% of total) (20).
Luciferase assays were conducted as described below with the exception that the
emitted light was quantitated for 20 s with a Monolight 2010 luminometer
(Analytical Luminescence Laboratory) and 15 ml of extract was used.
RNA isolation for Northern blotting and RPAs. Total RNA was isolated from
C57BL/6 mice by guanidinium isothiocyanate-cesium chloride centrifugation (3).
A riboprobe specific for both MLC1 and MLC3 transcripts was generated by
cloning a 293-bp PCR product from mouse skeletal muscle cDNA containing
exons 2 and 3 (specific for MLC3) and exons 5 and 6 (common exons) into the
SmaI site of pBluescript KS (Stratagene) (Fig. 1). Antisense RNA probes la-
belled with 32P were generated by in vitro transcription with T3 RNA polymerase
of the BamHI-digested mouse construct. RNase protection assays (RPAs) were
performed with 10 mg of cesium chloride-purified RNA as described previously
(74). For Northern blot analysis, 10 mg of total RNA per lane was electropho-
resed on a 1.5% gel and hybridized with a 32P-labelled probe to the 293-bp
mouse DNA fragment generated by priming with random oligonucleotides (Am-
ersham).
Quantitation of genomic methylation. Quantitative analysis of genomic meth-
ylation was carried out by restriction enzyme analysis coupled with ligation-
mediated PCR (LMPCR) (45, 61). For promoter of enhancer analysis, 1 or 2 mg
of DNA, respectively, was digested overnight with a 10-fold excess of AflII (New
England Biolabs) or PvuII (New England Biolabs) restriction enzyme units per
microgram. The DNA was ethanol precipitated and digested overnight with
equal amounts of MaeII (Boehringer Mannheim) or HhaI (New England Bio-
labs) restriction enzymes, respectively, followed by ethanol precipitation and
LMPCR.
PCR was performed with the restriction-digested genomic DNA samples as
originally described (18, 50) and as modified by McGrew and Rosenthal (45). For
quantitation of methylation, the labelled DNA samples were run on a 6%
acrylamide sequencing gel (0.4-mm thickness). The gel was dried and exposed,
and the intensities of the bands in the autoradiograph were quantitated with a
scanning densitometer (Molecular Dynamics). The primers used for the en-
hancer analysis have been described previously (24). The primers used for the
endogenous rat and transgenic rat MLC3 promoters were R3P-1, AAA ACA
GCA GCG GGA CTG; R3P-2, AAC TGA AGA CAC CTC CAG TGG GTC;
and R3P-3, TCC AGT GGG TCC CTG AGT GGA GTC C.
In situ hybridizations. Transgenic mouse embryos were identified by PCR of
CAT sequences from genomic DNA isolated from the amnion of each embryo.
The morning of the vaginal plug formation was designated 0.5 day postcoitum
(dpc). Embryo fixations and in situ hybridizations were performed as previously
described (25, 59). The MLC3 probe was prepared as previously described (42)
with an oligonucleotide corresponding to the 59 untranslated region of the mouse
MLC3 gene (56) cloned into a Bluescript vector, to eliminate cross-hybridization
with other members of theMLCmultigene family. The CAT probe was prepared
as previously described (25).
Rat primary cultures and transfections. Primary myocytes were isolated from
1-day-old neonatal rat pup hind limbs as previously described (11). Myoblasts
were grown in plating medium (Dulbecco modified Eagle medium [DMEM] plus
20% fetal calf serum, 2% glutamine, 12.5 U of penicillin-streptomycin per ml) for
3 days and transfected by calcium phosphate coprecipitation (22) with 10 mg of
the MLC3 test construct and 2 to 3 mg of a pSV2-CAT control construct
(Promega). After 24 h, the medium was changed to differentiation medium
(DMEM plus 4% horse serum, 2% glutamine, 12.5 U of penicillin-streptomycin
per ml). The cultures were harvested for luciferase assays after 2 days in the
differentiation medium.
Luciferase and CAT assays. Twenty microliters of rat primary cell extract (100
ml) was assayed for luciferase activity for 10 s in a Berthold LK 9200 luminometer
with the Promega luciferase assay system. The remaining extract (30 ml) was heat
treated for 10 min at 658C, and CAT activity was determined by the phase-
exchange assay (52).
RESULTS
MLC3 expression in adult skeletal and cardiac muscle tis-
sues. Previous studies have indicated that the MLC1 and
MLC3 promoters are differentially regulated and that the
MLC3 promoter displays transcriptional activity without the
downstream enhancer in primary muscle cell cultures (57, 60).
Recently it was shown that a large intronic fragment containing
the mouse MLC3 promoter and a 260-bp downstream en-
hancer was sufficient to drive CAT transgene expression in
skeletal and cardiac muscles (33). We therefore decided to
perform a detailed comparison of endogenous MLC1 and
MLC3 expression in adult tissues. Northern blot analysis of
total RNA from adult mouse tissues revealed a transcript in
the atria which comigrated with the MLC3-specific transcript
in the diaphragm (Fig. 2). To eliminate possible artifacts aris-
ing from cross-hybridization of the probe with other myosin
light chains which have high levels of sequence identity, we
performed RPAs of mouse tissues with a mouse cDNA ribo-
probe which could distinguish MLC1 and MLC3 transcripts
(see Materials and Methods) (Fig. 1). The MLC3 transcript
was present in the atria and at a lower level in the ventricles
FIG. 2. MLC3 transcripts are present in mouse atria. Northern blot contain-
ing 10 mg of total RNA per lane was hybridized with a mouse cDNA probe to
MLC3-specific exons and common exons. The MLC1 transcript is 1,050 bp, and
the MLC3 transcript is 900 bp.
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(Fig. 3). The amount of transcript was equal in intensity to
expression in the soleus, a low expressor of MLC1 and MLC3.
A faint lower band specific for common exons 5 and 6 was also
visible in heart tissue and possibly represents an MLC3 tran-
script which was not yet fully spliced. Additional transcripts
were not detected in any other mouse tissues (data not shown).
In addition, MLC3 transcripts were also detected in the atria
and ventricles of rat and canine hearts (44a). Therefore, the
internal MLC3 promoter is transcriptionally active in both
mammalian skeletal and cardiac muscles.
Temporal expression of MLC1 and MLC3 in striated mus-
cle. To examine the spatial and temporal expression patterns of
MLC1 and MLC3 transcripts during embryogenesis, we as-
sayed tissues of limb, body wall, and cardiac muscles at staged
developmental times (Fig. 4). Previous studies have shown that
the MLC1 promoter is first transcribed at 9.5 dpc in the myo-
tome, and theMLC3 promoter is transcribed at 15.5 dpc in the
axial and limb musculature (42). Accordingly, we detected the
MLC1 transcript at 12.5 dpc in trunk and limb muscles. At later
stages this transcript increased linearly. In contrast to previous
reports, a low level of theMLC3 transcript was detected at 12.5
dpc. MLC3 transcripts dramatically increased between 14.5
and 16.5 dpc, concomitant with the formation of secondary
muscle fibers and polyinnervation. The increase inMLC3 tran-
script accumulation at 15.5 dpc has been shown to be caused by
an increase in the rate of transcription of the MLC3 promoter
(10).
The expression of the MLC3 transcript in cardiac tissue was
first assayed by RPA at 12.5 dpc and was found to be expressed
in the atria at a level equivalent toMLC1 expression in skeletal
muscle (upper band versus lower band). The endogenous tran-
script was also detected at 11.5 dpc by in situ hybridization and
was restricted to the atria (Fig. 5). The expression levels in
cardiac muscle remained constant throughout embryogenesis
and persisted in the adult. This comparison reveals new aspects
of the differential regulation of the MLC3 promoter in cardiac
and skeletal muscles during development. While expression in
the atrium is initiated at early embryonic stages and is constant,
skeletal muscle-specific expression begins at very low levels, at
stages earlier than previously reported, and undergoes a dra-
matic upregulation during the fetal stage of mouse develop-
ment.
MLC3 regulatory elements drive reporter gene expression in
vivo in both skeletal and cardiac muscle lineages. To define
the cis regulatory elements responsible for the skeletal and
cardiac muscle expression of MLC3, we generated transgenic
mice containing a 628-bp MLC3 promoter fragment driving a
CAT reporter construct with or without a downstream MLC
enhancer fragment (Fig. 1). As shown in Table 1, analysis of
CAT activity in several independent lines revealed that the
MLC3 promoter alone was sufficient to drive transgene expres-
sion in cardiac muscle tissue. MLC3CAT transgene expression
most resembled the endogenous pattern of expression in car-
diac muscle in two transgenic lines, 479 and 533, which showed
higher levels of expression in the atria than in the ventricles.
Further, the level of ventricular expression in all cardiac mus-
cle lines expressingMLC3 (excluding line 533) was higher than
expected in comparison to atrial and skeletal muscle transgene
expression. In situ hybridizations on transgenic embryos from
line 479 demonstrate that the MLC3 promoter drove correct
temporal expression in the atria of mice at 11.5 dpc although
no signal was detected in any embryonic muscle masses (Fig. 5
and data not shown). Surprisingly, the MLC3 promoter also
proved to be sufficient to activate high levels of skeletal muscle
transgene expression in some adult muscle groups without the
downstreamMLC enhancer. This transgene expression did not
correlate well with endogenous MLC3 expression. The level of
the endogenous MLC3 gene is expressed highest in muscles
that contain a high percentage of fast-type 2B fibers, such as
the extensor digitalis longus (EDL), and lowest in the dia-
phragm and the soleus, which predominately do not express
fast-type 2B muscle isoforms (64, 65). The majority of trans-
genic MLC3CAT lines expressed the CAT gene in most adult
skeletal muscles groups assayed, although different muscle
groups displayed various levels of CAT activity in each line.
These differences can presumably be attributed to position
effects.
Additional transgenic lines containing either a 180- or
920-bp MLC downstream enhancer element, MLC3CAT180
and MLC3CAT920, demonstrated an increased range and
level of transgene expression in skeletal muscle. This is exem-
plified by the expression of CAT transcript in the EDL, the
highest expressor of endogenous MLC3 transcript, and by the
increase in CAT expression levels in the intercostal muscles
relative to the levels in other muscle groups (Table 1, lines 552
FIG. 3. MLC3 expression pattern in various cardiac and skeletal muscle
tissues. RPAs were performed with 2 mg of mouse total RNA (overnight expo-
sure) (A) or 5 mg (2-day exposure) (B) with a mouse probe specific toMLC1 and
MLC3 (see Materials and Methods).
FIG. 4. Development expression of MLC3 transcripts in the striated muscu-
lature. RPAs were performed with 5 mg of mouse total RNA (2 mg from an adult
diaphragm), isolated at the indicated times, with a probe specific to MLC1 and
MLC3. (A) Skeletal muscle tissue; (B) cardiac muscle tissue. Neo, neonatal.
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and 193). Unexpectedly, most lines containing the MLC en-
hancer element no longer expressed the CAT transgene in
cardiac muscle tissue. This may be due to the close juxtaposi-
tion of the promoter and enhancer elements in the concate-
nated transgenes. In summary, the expression patterns ob-
tained in transgenic mice demonstrate that regulatory
elements sufficient to drive transgene expression in embryonic
and adult cardiac muscles are present in the proximal MLC3
promoter. This regulatory region is also able to activate ex-
pression in most adult skeletal muscle groups, although the
complete skeletal muscle phenotype is not generated in the
absence of the downstream distal enhancer.
Previous work has demonstrated that the MLC1 promoter
and 920-bp enhancer driving a CAT reporter construct gener-
ated a gradient of expression in the intercostal muscles. Re-
cently, in a transgenic mouse the murine MLC3 promoter and
a 260-bp enhancer fragment driving a lacZ transgene were
reported to not be expressed in a gradient in the intercostal
muscles (33). In contrast to these results, several MLC3CAT
transgenic lines containing the promoter alone (lines 479 and
459) or with the downstream enhancer (lines 690, 194, and
256) displayed a significant gradient of expression in the inter-
costal muscles (4- to 40-fold). This suggests that redundant cis
elements present in the MLC3 promoter and MLC enhancer
regulatory regions are responsible for the gradient of trans-
gene expression.
Differential methylation of regulatory regions in theMLC1/3
locus. Previous studies of the endogenous MLC1/3 locus have
implicated DNA methylation in the control of gene expression
during embryogenesis and in different adult muscle groups.
Examination of the MLC1/3 locus in the chicken showed that
the late activation of transcription of the MLC3 promoter
corresponded with the timing of demethylation of promoter
CpG dinucleotides (37). The endogenous rat MLC1 promoter
and enhancer also displayed muscle-specific demethylation
(45, and this paper). Both elements were highly methylated in
cardiac and nonmuscle tissues. In addition, transgenic mice
carrying theMLC1 promoter driving a CAT reporter gene with
the downstream MLC enhancer exhibited muscle-specific ex-
pression which closely correlated with demethylation levels of
both promoter and enhancer elements (14, 24). We investi-
gated the methylation status of a CpG dinucleotide located at
2175 bp in the rat MLC3 promoter (Fig. 1), using a quantita-
tive PCR-based technique (45, 61). This method combines the
use of methylation-sensitive restriction enzymes with LMPCR
to generate two amplified DNA products whose ratio corre-
lates with the level of methylation at the site being assayed. We
found that unlike the MLC1 promoter and MLC enhancer
which are demethylated in a muscle-specific pattern, the CpG
sequence analyzed in the endogenous MLC3 promoter was
demethylated ubiquitously. We extended this analysis to exam-
ine the methylation pattern in transgenic mice containing the
MLC3 promoter and the 920-bp downstream MLC enhancer
element driving a CAT reporter construct. As seen in Fig. 6,
the transgenic MLC3 promoter was ubiquitously demethyl-
ated, while the MLC enhancer was demethylated solely in
muscle tissue. This study demonstrates that methylation pat-
FIG. 5. Distribution ofMLC3 endogenous andMLC3CAT transgene in embryonic hearts at 11.5 dpc. Dark-field micrographs ofMLC3 (a) and CAT (b) transcripts
in parallel parasagittal sections from a transgenic animal at 11.5 dpc (transgenic line 479). Endogenous expression is predominately localized over the atria while CAT
expression is detectable in the ventricle. (c and d) Bright-field micrographs of panels a and b, respectively. RBC, red blood cells; A, atrium; V, ventricle.
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terns in vivo are established independently on the multiple
regulatory regions of this locus.
In vivo analysis of cardiac muscle-specific elements in the
MLC3 promoter. To further extend the transgenic analysis of
MLC3 regulation, and to delineate the cis elements responsi-
ble for cardiac muscle-specific expression, we assayed activity
of theMLC3 promoter driving a luciferase reporter gene when
directly injected into adult rat ventricles. Direct DNA injec-
tion results in specific transfection into myocytes and has
been shown to be useful for the analysis of cardiac regulatory
regions in vivo (7, 34, 35). Luciferase reporter constructs
are commonly used for cardiac injections because of the in-
creased sensitivity of the luciferase assay. Figure 7A shows
the expression pattern obtained for MLC3Luc constructs in
cardiac tissue. Comparison of MLC3Luc reporter constructs
MLC628Luc and MLC628Luc920 indicated no increase in ex-
pression with the presence of the downstream enhancer. These
data support our results obtained with transgenic lines indicat-
ing that cardiac regulatory elements are located in the 628-bp
proximal promoter and not in theMLC enhancer. Deletions of
the promoter alone to 2434 and 2257 bp did not cause a
substantial loss of activity. This demonstrates that three E
boxes present in this 371-bp upstream region are not necessary
for cardiac activity. A further deletion to 2147 bp led to a
dramatic loss of activity (20-fold), indicating the presence of a
positive cardiac element in this region. An MEF2 consensus
site located at 2155 bp was deleted in this construct. To de-
termine whether the MEF2 site was functional, we mutated the
consensus sequence in the context of the 628-bp MLC3 pro-
moter fragment. Additionally, a repeated binding motif for
another known cardiac transcription factor, GATA-4, located
at260 bp, was also mutated. Mutation of either the MEF2 site
or the GATA site caused a dramatic reduction (10-fold) in
activity compared with that of the intact promoter. These re-
sults demonstrate that the proximal 257 bp of the MLC3 pro-
moter are sufficient for cardiac muscle-specific activity and that
the MEF2 and GATA sites present in the proximal promoter
region are both singularly necessary for its cardiac muscle-
specific expression.
Analysis of skeletal muscle-specific elements of the MLC3
promoter. To compare the function of MLC3 regulatory ele-
ments in skeletal versus cardiac muscles, we analyzed the ex-
pression profile of MLC3Luc constructs in transient transfec-
tions of primary skeletal muscle cultures. Rat primary cultures
were chosen because, unlike established muscle cell lines, they
contain regulatory factors able to activate theMLC3 promoter
without the presence of the downstream enhancer (57, 60). As
seen in Fig. 7B, a construct containing the MLC3 promoter
alone was 25% as active as a construct containing both the
promoter and MLC enhancer. Deletions of the MLC3 pro-
moter alone to 2257 bp did not decrease its activity, as was
also seen for cardiac injections. These data indicate that the
three upstream E boxes in the MLC3 promoter are not nec-
essary for expression in skeletal or cardiac muscle. However,
an additional deletion to 2147 bp resulted in a loss in activity
(twofold). This deletion removes the single MEF2 site in the
MLC3 promoter. Mutating the MEF2 site in the context of the
entire 628-bp promoter also resulted in a twofold loss of ac-
tivity. These results suggest that MEF2 is more important for
MLC3 promoter function in cardiac muscle than in skeletal
muscle. In addition, the construct containing a mutation of the
GATA site in the context of the full-length promoter also
showed a significant loss of activity (10-fold). This result was
unprecedented since GATA-binding factors have not previ-
ously been shown to be involved in skeletal muscle-specific
gene expression. In summary, both MEF2 and GATA sites
located in the proximal MLC3 promoter are required for ac-
tivity in both striated muscle lineages.
Tandem GATA binding sites in the proximal MLC3 pro-
moter bind with high affinity to mouse GATA-4 protein. The
repeated GATA sequence at 260 bp in the MLC3 promoter
does not strictly conform to the consensus GATA protein-
binding site, A/T GATA A/G. However, GATA protein family
members have been shown to bind specifically to sequences
divergent from the consensus sequence (36, 46). To determine
if the MLC3 promoter element was a specific binding site for
GATA proteins, EMSAs were carried out with an oligonucle-
otide containing the double GATA site as a probe and in
vitro-transcribed-translated mouse GATA-4 protein. As seen
in Fig. 8, a shifted complex was present in the lane containing
GATA-4 protein. Competition with 200- to 400-fold excess of
cold wild-type GATA oligonucleotide resulted in the loss of
this complex, while competition with cold mutated oligonucle-
otide did not. Therefore, the GATA element present in the
TABLE 1. Expression of MLC3 constructs in transgenic mouse lines
Construct and cell line
% of CAT activity in tissue froma:
Liver Lung Spleen Atria Ventricle Masseter Dig Dia Tricep Pec Thigh Soleus EDL RIC MIC CIC
MLC3CAT
459 2 2 2 111 111 2 2 2 111 111 6 2 2 2 6 1
533 2 2 2 111 2 2 111 2 2 2 1 1 2 2 2 2
479 2 2 2 11 1 2 2 6 1 11 111 2 1 6 6 1
MLC3CAT 180-bp enhancer
552 2 2 2 11 11 111 ND 111 111 1 111 11 111 111 111 111
599 2 2 2 2 2 1 2 2 111 111 111 6 11 111 111 111
690 2 2 2 2 2 2 2 2 11 11 111 6 11 1 1 11
MLC3CAT 920-bp enhancer
1 2 2 2 11 11 111 ND 6 1 2 11 2 111 1 2 6
193 2 2 2 2 2 2 2 2 111 111 111 6 111 1 1 11
194 2 2 2 2 2 2 2 2 11 11 11 6 11 11 111 111
a Relative CAT activity, normalized to the protein concentration, was determined in the indicated tissues for transgenic mice from each transgenic line (highest level
in tissue set to 100). A minimum of two animals were assayed for each line, and the expression pattern is shown for a single representative animal. Expression levels
varied highly between cell lines containing the same construct (100-fold). Lines 479, 552, and 193 were the highest expressors for their constructs and had comparable
copy numbers, and levels of CAT activity (25 mg of total protein assayed for 1 h gave 25% conversion to the acetylated form). Dig, Digastricus; Dia, Diaphragm; Pec,
pectoralis; EDL, extensor digitalis longus; RIC, MIC, and CIC, rostral (1 to 3), mid (5 to 6), and caudal (9 to 10) muscles of intercostal muscles 1 to 12, respectively.
CAT activity: 0 to 3% (2), 4 to 9% (6), 10 to 20% (1), 21 to 50% (11), 51 to 100% (111). ND, not determined.
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MLC3 promoter is not only functionally important for tran-
scriptional activity in striated muscles but comprises a se-
quence-specific binding site for GATA proteins.
DISCUSSION
This report documents the expression of fast skeletal muscle
MLC3 in cardiac muscle tissue and delineates regulatory re-
gions in theMLC1/3 locus responsible for this expression in the
proximal promoter region. MLC3 expression in cardiac tissue
is activated early and is constant throughout development
whereas skeletal muscle MLC3 expression is present in early
embryos at very low levels and undergoes a dramatic increase
at 14.5 dpc. The present study extends previous analyses of
MLC regulation to show that reporter gene expression both in
transgenic animals and direct cardiac injections reveals that the
downstream MLC enhancer is not involved in cardiac tran-
scription and may actually silence cardiac expression when
placed close to the promoter element. However, high levels of
MLC3 expression in skeletal muscle in vivo appear to rely on
the enhancer element. Mutational analysis of the MLC3 prox-
imal promoter region has identified two sequence motifs,
MEF2 and GATA, which are important for expression in both
skeletal and cardiac muscles. The GATA element is further
shown to bind in a sequence-specific manner to GATA-4 pro-
tein. Finally, the MLC3 promoter is ubiquitously demethyl-
ated. This is in contrast to the upstreamMLC1 promoter or the
downstream enhancer which exhibits tissue-specific demethy-
lation. These results emphasize the differential regulation of
the internal MLC3 promoter.
Expression of MLC3 in the mouse atrium is unexpected,
considering that the alkali myosin light chain, MLC1A, is
highly expressed in this cardiac domain. It is conceivable that
before the expansion of the alkali myosin light-chain gene
family, anMLC3-like gene was expressed to a greater extent in
cardiac tissue. Barton and Buckingham (5) argued that the
antecedent MLC would most resemble MLC3 on comparison
of intron and exon structures and the sequence of the locus in
different species. This is supported by the similarity of MLC3
and the single Drosophila alkali MLC, MLC-alk, which pos-
sesses a similar exon/intron structure, contains a separate first
exon encoding the initiator methionine codon (62), and is
expressed throughout the fly striated musculature (16, 17).
Examination of MLC-alk upstream promoter regions reveals
the presence of an MEF2 and a repeated GATA motif (17),
indicating these regulatory elements may be evolutionarily
conserved. Future work will determine if other vertebrate or-
ganisms retain cardiac expression of the MLC3 gene or if this
potentially vestigial expression pattern is peculiar to mammals.
Transcriptional activation of the MLC3 promoter in striated
muscle tissues appears to depend on MEF2 and GATA sites in
the proximal promoter region. By contrast, it appears that
three upstream E boxes are not required for promoter activity.
It is possible that the MEF2 and GATA sites coordinate the
activity of separate upstream regulatory regions which drive
transcription in cardiac or skeletal muscle tissues. For example,
Iannello et al. (28) observed that the activity of the cardiac
troponin T gene in skeletal and cardiac muscles depended on
two separate promoter regions which acted through common
proximal elements. Notably, the three MLC3CAT transgenes
analyzed here are expressed exclusively in a subset of skeletal
muscle fibers that express the endogenous gene (IIX or IIA
[52a]), indicating that other regulatory regions may contribute
to the full spectrum of endogenous MLC3 expression. For
example, it is likely that other intronic regions in the MLC
locus may be involved in expression from theMLC3 promoter.
A single transgenic line that contains an additional 1.4 kb of
MLC3 promoter sequence and the entire second intron ex-
pressed in all skeletal muscle groups suggest the existence of
other positive regulatory regions of the MLC3 promoter in the
mouse locus (33). Moreover, since the transgene analyzed in
that study also included promoter regions containing the con-
served MEF2 and GATA motifs, it is likely that these elements
will be key components in driving the striated muscle expres-
sion from the MLC3 promoter. Altogether, it appears that the
internalMLC3 promoter is sufficient for transcriptional activity
in most striated muscle tissues, although this expression may be
modulated by additional regulatory regions.
Mutational analysis of the MEF2 site in theMLC3 promoter
indicates that this motif is necessary for MLC3 expression in
cardiac muscle and to some extent in skeletal muscle. MEF2
sites have been shown to be involved in the cardiac and skeletal
muscle expression of several genes (21, 48, 51). In a tissue
culture model of hypertrophy, the HF-1 site in the MLC2
promoter, which contains an MEF2 binding site, has been
shown to be important for inducible expression during hyper-
FIG. 6. Methylation of regulatory elements in MLC locus. Demethylation levels were determined at CpG sites in the MLC1 promoter, the MLC3 promoter, and
the downstream MLC enhancer of the endogenous rat locus (41) or of transgenic mice carrying the MLC1CAT920 transgene (23) or the MLC3CAT920 transgene
(transgenic lines 1, 193, and 228). Genomic DNA was isolated from adult tissues (rat liver and extensor digitalis longus; mouse liver and thigh). The percent
demethylation was calculated from photodensitometric scans of labelled LMPCR products analyzed by gel electrophoresis and autoradiography. The values shown are
the averages from three to six independent experiments with a minimum of two animals; error bars indicate standard errors. 1, nonmuscle; n, muscle.
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trophy (73). Furthermore, the correct spatial and temporal
expression of the myogenin promoter in transgenic mice was
shown to depend on the presence of an MEF2 site (9, 70). The
role of this transcription factor in regulating expression of
striated muscle-specific structural proteins in vivo is still un-
clear. The protein isoforms MEF2A and MEF2C are known to
be expressed in both of these tissues and to activate gene
expression from multimerized binding sites in cell culture (32).
Future experiments will determine if a specific member of this
family interacts with the MLC3 promoter in both skeletal and
cardiac muscles.
This report also defines a GATA element that is necessary
for MLC3 skeletal and cardiac muscle-specific expression and
binds GATA-4 protein with high affinity. GATA sites are also
necessary for expression of the a-MHC and BNP promoters in
cardiac tissue, and these genes are transactivated by the tran-
scription factor, GATA-4 (23, 29, 48). The MLC3 gene joins a
number of other genes such as MLC1A, BNP, MLC2, and
a-MHC whose domain of expression includes the atria (6, 23,
39, 41). Comparison of the MLC3 promoter region with the
regulatory regions of these genes indicates that they also con-
tain a repeated GATA motif separated by 3 to 7 bp. Since
GATA proteins bind their consensus sites with equal affinity
(52b), it is likely that the subset of GATA factors abundant in
cardiac tissue (38) and in other embryonic tissues (19, 26, 69)
are all capable of binding with similar affinity to the GATA
motif in the MLC3 promoter (36, 46).
This report is also the first documentation of the involve-
ment of a GATA motif in skeletal muscle-specific expression.
GATA-2 and GATA-3 are expressed in many tissues outside
of the erythrocyte lineage (19, 69) and may be involved in
muscle gene expression. Although no systematic analysis of
GATA factor expression in skeletal muscle has been reported,
both GATA-2 and -3 transcripts are present in both skeletal
muscle tissues and cell lines (44). It remains to be determined
if a novel muscle-specific factor acts through this site or if one
of the known GATA transcription factors is responsible for
MLC3 activity.
In contrast to mechanisms activating gene transcription
through cell-specific trans-acting factors, epigenetic modifica-
tions have been shown to play a role in establishing accessibil-
ity to and spatial expression of tissue-specific genes (reviewed
in reference 8). In particular, skeletal muscle genes undergo a
tissue-specific demethylation of regulatory regions (71). The
CpGs analyzed in theMLC1 promoter and theMLC enhancer
follow this pattern and undergo a tissue-specific demethyla-
FIG. 7. MLC3 activity in cardiac and skeletal muscles. (A) Luciferase activity in MLCLuc constructs was assayed in injected rat hearts (see Materials and Methods).
Injected plasmid DNA consisted of the 628-bp MLC3 promoter driving a luciferase reporter gene (p628Luc) or 59 deletions of that construct (p434Luc, p257Luc, and
p147Luc). The MEF2 site or GATA site was mutated separately in the construct p628Luc, p628LucmMEF, and p628LucmGATA, respectively. The 920-bp rat MLC
enhancer was cloned downstream of the luciferase gene (p628Luc920). Injections were normalized to CAT activity and shown relative to that of the p628Luc construct
(set to 100). The numbers in parentheses indicate the number of animals assayed. (B) Neonatal rat primary skeletal muscle cultures were transfected with the plasmids
described for panel A. Transfections were normalized to CAT activity and shown relative to that of the p628Luc construct (set to 100). Each transfection is a minimum
of three separate transfections. Error bars indicate standard errors.
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tion. However, the CpG analyzed in the proximal MLC3 pro-
moter is demethylated in all tissues. The lack of tissue-specific
demethylation in the MLC3 promoter may be a component of
differential regulation of MLC3 expression in both skeletal and
cardiac muscle. In addition, the activation of the upstream
MLC1 promoter precedes the MLC3 promoter during embry-
onic development. This results in transcripts from the MLC1
promoter extending through the downstream MLC3 promoter
region before the latter is transcriptionally active. It remains to
be determined if the chromatin structure of the MLC3 regu-
latory region assumes an active conformation at these early
embryonic stages which may preclude the regulatory control of
the MLC3 promoter by methylation. In conclusion, these re-
sults provide evidence for independent differential epigenetic
regulation of the two MLC fast muscle isoforms, which may
underscore their specific roles in muscle function.
In summary, analysis of the MLC3 promoter in vitro and in
vivo has identified common cis elements driving skeletal and
cardiac muscle-specific expression. Current experiments are
focused on defining the transcription factors interacting with
these elements in both striated muscle lineages. These findings
will help in the further identification of the members of regu-
latory gene families involved in the expression of genes in
subdomains of skeletal and cardiac tissues.
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